Vonoprazan fumarate
|
|
|
- CAS-Nr.
- 1260141-27-2
- Englisch Name:
- Vonoprazan fumarate
- Synonyma:
- Vonoprazan FuMarate;Vonaprazan;5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine 2-butenedioate (Vonoprazan);Vonaprazan(TAK-438);Vonoprazon Fumarate;Vonoprazan fumarate(TAK-438);vonoprazan(tak-438)1260141-27-2;5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine 2-butenedioate;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine,(E)-4-oxopent-2-enoic acid;AK-438
- CBNumber:
- CB32628441
- Summenformel:
- C21H20FN3O6S
- Molgewicht:
- 461.4634032
- MOL-Datei:
- 1260141-27-2.mol
|
Vonoprazan fumarate Eigenschaften
- storage temp.
- Store at -20°C
- Löslichkeit
- insoluble in H2O; insoluble in EtOH; ≥18.9 mg/mL in DMSO
- Aggregatzustand
- solid
- InChIKey
- ROGSHYHKHPCCJW-WLHGVMLRSA-N
- SMILES
- N1(S(C2=CC=CN=C2)(=O)=O)C(C2=CC=CC=C2F)=CC(CNC)=C1.C(O)(=O)/C=C/C(O)=O
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P271 |
Nur im Freien oder in gut belüfteten Räumen verwenden. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P302+P352 |
BEI BERÜHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckmäßig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
| P304+P340 |
BEI EINATMEN: Die Person an die frische Luft bringen und für ungehinderte Atmung sorgen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
| P312 |
Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P321 |
Besondere Behandlung |
| P332+P313 |
Bei Hautreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
| P337+P313 |
Bei anhaltender Augenreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
|
Vonoprazan fumarate Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Vonoprazan fumarate (Takecab®), discovered and developed by
Takeda and Otsuka, was approved by the PMDA of Japan in
December 2014, and is indicated for the treatment of gastric ulcer,
duodenal ulcer and reflux esophagitis. Vonoprazan fumarate has
a novel mechanism of action called potassium-competitive acid
blockers, which competitively inhibit the binding of potassium
ions to H+, K+-ATPase (also known as the proton pump) in the final
step of gastric acid secretion in gastric parietal cells. Vonoprazan
does not inhibit Na+, K+-ATPase activity even at concentrations 500
times higher than that of their IC50 values against gastric H+,
K+-ATPase activity. Furthermore, the drug is unaffected by the
gastric secretory state, unlike PPIs.
Verwenden
Vonoprazan Fumarate is a novel potassium-?competitive acid blocker for the treatment of acid-?related diseases.
Application
Vonoprazan fumarate is an oral, newly synthesised potassium-competitive acid blocker (P-CAB) with antisecretory activity. It is also a proton pump inhibitor (PPI) reversibly inhibiting H+/K+, ATPase. It is mainly used in the treatment of acid-related diseases such as GERD and peptic ulcer disease.
Synthese
Commercially
available 2-fluoroacetophenone (283) was brominated to yield
a-bromo-acetophenone derivative 284. This compound was
treated with ethyl 2-cyanoacetate (285) under basic conditions
to provide ketoester 286 in essentially quantitative yield. Next,
intramolecular condensation of 286 upon treatment of 4 M HCl
furnished the tri-substituted pyrrole 287 in 53% yield. Reduction
of the chloride under hydrogenolytic conditions facilitated arrival
at pyrrole 288, albeit in just 18% yield. Subsequent diisobutylaluminium
hydride (DIBAL) reduction, followed by the oxidation with
tetrapropylammonium perruthenate (TPAP) and 4-methylmorpholine
N-oxide (NMMO) afforded the corresponding aldehyde 290 in 60% yield across the 2 steps. Next, N-pyrrole substitution with pyridine-
3-sulfonyl chloride 291 gave rise to N-sulfonylpyrrole 292 in
82% yield. Reductive amination of 292 afforded amine 293, which
was treated with fumaric acid (294) via co-crystallization to provide
vonoprazan fumarate (XXXVI) in 74% for the two steps.
Vonoprazan fumarate Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Vonoprazan fumarate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 474)Lieferanten
1260141-27-2()Verwandte Suche:
- 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine
- AK-438
- vonoprazan(tak-438)
- fuMarate vonoprazan
- 1H-Pyrrole-3-methanamine, 5-(2-fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-, 2-butenedioate (1:1)
- 5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine 2-butenedioate TAK 438
- vonaprazan(TK-438)
- TAK-438
Vonoprazan fumarate
- VONOPRAZAN FUMARATE (TAK-438);TAK-438
- TAK 438,Vonoprazan
- TAK-438
- 1-(5-(2-FLUOROPHENYL)-1-(PYRIDIN-4-YLSULFONYL)-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE
- 4-Aminopyrazolo[3
- vomoprazan fumarate
- Vonoprazan Fumarate-D3Q: What is
Vonoprazan Fumarate-D3 Q: What is the CAS Number of
Vonoprazan Fumarate-D3
- Vonoprazan Vonoprazan onoprazan Vonoprazan fumarate
- Vonorasen fumarate
- Vonoprazan fumarate API
- Vonoprazan Fumarate
DISCONTINUED PLEASE SEE V767013
- TAK-438 ISO 9001：2015 REACH
- TAK-438 USP/EP/BP
- TAK-438,1260141-27-2 Fluorine Prazan
- 5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine 2-butenedioate (Vonoprazan fumarate)
- Wonarazan Fumarate
- CS-597
- TAK 438; TAK438
- Vonoprazan-025-Salt2
- Vonolazan Fumarate API
- Vonaprazan
- 5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine 2-butenedioate (Vonoprazan)
- Vonaprazan(TAK-438)
- Vonoprazan fumarate(TAK-438)
- vonoprazan(tak-438)1260141-27-2
- 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine,(E)-4-oxopent-2-enoic acid
- Vonoprazan FuMarate
- 5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine 2-butenedioate
- Vonoprazon Fumarate
- Vorolazan fumarate
- Fumarate vonolasan
- 1260141-27-2
- 88168-00-2
- 260141-27-2
- C17H16FN3O2SC4H4O4
- Vonoprazan
- Inhibitors
- API
- 1260141-27-2
